Podcast · Episode 65

    Why Clinical Trials Are the Most Expensive Capital Outlay for Startups with Rob Bedford, CEO of Franklyn Health

    With Rob Bedford

    All episodes
    Episode 65: Why Clinical Trials Are the Most Expensive Capital Outlay for Startups with Rob Bedford, CEO of Franklyn Health

    Listen to episode 65

    Episode summary

    Rob Bedford discusses how clinical planning can protect startup resources before expensive studies begin. He connects target markets with study strategy and explains why careful partner selection, early regulatory feedback, and clear accountability matter when outside organizations perform the work.

    Key points

    • Planning studies around target markets
    • Early regulatory feedback
    • Accountability when working with contractors

    More on FDA Premarket Cybersecurity